ThromboGenics´ JETREA® Gains Approval in Singapore
Leuven, July 3, 2014 – ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that JETREA® (ocriplasmin) has been approved in Singapore for the treatment of adults with vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. Singapore is the second country in Asia to grant JETREA® approval, following Malaysia in April.
ThromboGenics’ partner Alcon, which is commercializing JETREA® outside the US, will be responsible for the launch of the drug in Singapore.
JETREA® is the first-in-class pharmacological treatment for this indication and was approved by the European Commission in the European Union in March 2013.